MedMira Announces Board Change

About this update from Medmira Inc.

[{"type":"text","content":"\n\n\n\nHALIFAX, July 18 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today\nthat Dr. Michael Thompson has resigned from the Board of Directors.\n\n\n"We appreciate the contributions Dr. Thompson has made to the Company and\nwish him well in future endeavours," said Stephen Sham, Chairman of the Board.\n\n\nAbout MedMira\n\n\nMedMira is a leading developer, manufacturer, and marketer of advanced\nrapid diagnostics. Built on the Company's patented rapid flow-through\ntechnology platform, MedMira's single and multiple rapid tests provide\nhospitals, labs, clinics and individuals around the world with reliable,\ndiagnosis for diseases such as HIV and hepatitis C in just three minutes. The\ncompany's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM)\nand Multiplo(TM) brands in global markets, have achieved regulatory approvals\nin Canada, the United States, China, Russia, India, and the European Union.\nMedMira is an approved supplier to US Agency for International Development\n(USAID) and the Pan American Health Organization (PAHO).\n\n\nIn 2006, MedMira launched the Maple Biosciences division to develop and\ncommercialize diagnostic instruments based on biosensor technology platforms.\nThe new diagnostic solutions will enable routine laboratory tests to be\nperformed in a matter of minutes, increasing automation, and streamlining the\ndiagnosis of multiple conditions and diseases. Together MedMira and Maple\nBiosciences will be leading participants in the emerging fields of\npersonalized medicine and molecular diagnostics. For more information visit\nwww.maplebio.com.\n\n\nMedMira's corporate offices, R&D, and manufacturing facilities are\nlocated in Halifax, Nova Scotia, Canada. For more information visit MedMira's\nwebsite at www.medmira.com.\n\n\nThis news release contains forward-looking statements, which involve risk\nand uncertainties and reflect the company's current expectation regarding\nfuture events. Actual events could materially differ from those projected\nherein and depend on a number of factors including, but not limited to,\nchanging market conditions, successful and timely completion of clinical\nstudies, uncertainties related to the regulatory approval process,\nestablishment of corporate ...

More updates from Medmira Inc.